Status:
TERMINATED
Evaluating the Transporter Protein Inhibitor Probenecid In Patients With Epilepsy
Lead Sponsor:
Jim McAuley
Conditions:
Epilepsy
Eligibility:
MALE
18-65 years
Phase:
PHASE4
Brief Summary
The study is being done to understand why some patients with epilepsy (disease of recurrence of seizures) do not respond very well to drug treatment with anticonvulsants. Despite the availability of ...
Detailed Description
About 30% of patients with epilepsy are refractory to medical treatment (pharmacoresistant epilepsy). The cause of which is multifactorial. Multidrug resistance (MDR) causes decreased uptake of medici...
Eligibility Criteria
Inclusion
- Men with pharmacoresistant partial epilepsy defined as failure of two or more AEDs at a reasonable therapeutic dose
- Patient is able to understand and sign a consent form and able to keep a seizure calendar
- Patient is older than 18 years of age
- Patient is otherwise healthy by laboratory and physical examination
Exclusion
- Patient is currently taking phenytoin
- Patient has a history of an adverse reaction to phenytoin
- Patient has a history of gout disease, peptic ulcer disease, blood dyscrasias, or uric acid kidney stones
- Patient has an allergy to sulfa drugs or probenecid
- Patient has been exposed to probenecid or another known transporter inhibitor (verapamil, progesterone, etc) in the three months prior to enrollment
- Patient has a history of renal impairment (creatinine clearance \< 50 ml/min)
- Patient has a history of diabetes and is taking oral sulfonylurea agents
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00610532
Start Date
March 1 2006
End Date
June 1 2011
Last Update
May 14 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Ohio State University
Columbus, Ohio, United States, 43210